microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review. Front Immunol. 2024 Mar 28;15:1354613. doi: 10.33...
Of these 51% and 23% of the tumors are from the left hemicolon and rectum respectively, 83% were moderately differentiated and 86% were invasive adenocarcinoma. Observed mutations are 74% in patients with advanced stage CRC (P=0.006). Among patients with KRAS mutated CRC (CRC) isolated lung...
The KRAS mutant proteins that drive cancer development are highly similar in sequence and structure based on the structural, mutational, and biochemical data of Harvey-RAS (HRAS). Direct inhibitors are most likely to bind to the catalytic domain of KRAS [40]. Research on direct inhibition of KR...
For example, in the last few years, we've observed that mutations in KRAS predict resistance to anti-EGFR therapeutics in colon cancer. Earlier this year, the US Food and Drug Administration approved the first ever KRAS inhibitor for use in patients, in this case non-small cell lung cancer...
(0.63–2.30) 32/112 261/613 67/181 1.28 (1.09–1.51) 1.05 (0.67–1.64) Abbreviations: CI ¼ confidence interval; CRC ¼ colorectal cancer; HR ¼ hazard ratio; KRAS ¼ Kirsten Ras; MSI ¼ microsatellite instability; MSI-H ¼ high microsatellite instability; mut ¼ mutated; wt ...
This mutation confers a poor prognosis in the metastatic setting, and a high risk of cancer recurrence as seen in several studies [6–9]. It is mutated in one-third of all cancers including colon cancer and pancreatic cancer. In addition, the three human RAS genes (NRAS, HRAS, KRAS) ...
“This population of patients withKRASG12C-mutated colorectal cancer faces a poor prognosis, and there currently are no effective targeted therapies,” Kopetz said. “Therefore, it’s promising to see that this combination shows clinically meaningful benefit both in response rates and duration of di...
or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status.Conclusions: In this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on dis...
KRAS mutation testing in metastatic colorectal cancer The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and KRAS mutational status testing has been highlighted in recent years. The m... T Cong,D Xiang - 《World Journal of Gastroenterology》 被引量: 303发表: 2012年 ...
In KRAS-mutated tumours, other oncogenes or tumour suppressor genes may also be abnormal and may participate in immune escape together with KRAS mutation. For example, in lung cancer, coactivation of KRAS (G12D) and MYC drove the aggregation of anti-inflammatory macrophages, but the absence ...